Admedus is focused on developing, commercialising and distributing next-generation medical technologies with global potential.
Currently Admedus has two platform technologies:
- Our Tissue Engineering division uses our proprietary ADAPT® engineering process to produce implantable tissue bio-scaffolds for use in various soft tissue repair applications. The first ADAPT® engineered product to market is CardioCel®, a bio-scaffold patch for cardiac repairs and reconstructions.
- Our Immunotherapies division is working with scientist and Australian of the Year, Professor Ian Frazer, to develop vaccines for the treatment and prevention of infectious diseases and cancers with an initial focus on Herpes Simplex Virus (HSV-2) and Human papillomavirus (HPV);